ELEVECTA® – Helper virus-free AAV production with stable CAP® and HEK293 producer cell
Free Webinar, Dr. Silke Wissing, Chief Scientific Officer
Cell & Gene Therapy Manufacturing & Commercialization
Digital Week, February 19, 2021
ELEVECTA® – The future of AAV gene therapy vector production
Pharmaceutical companies with gene therapies in their pipeline need to establish scalable production processes that can keep up with the increasing demand in terms of volume, quality and robustness, says CEVEC.
BPI Contributor, November 3, 2020
How to Solve the Production Challenges of AAVs for Gene Therapy
CEVEC Pharmaceuticals has found a solution and developed a platform that can produce adeno-associated viral vectors (AAVs) as easily as if they were monoclonal antibodies.
Labiotech.eu – June 3, 2020
Read the interview with Nicole Faust, CEO of CEVEC
Scaling AAV vector manufacture: overcoming roadblocks to the translation of gene therapies
“The major challenge I anticipate will be to bring down production costs. The current price of gene therapies makes it inaccessible to so many patients worldwide.”
Read the interview with Nicole Faust, CEO of CEVEC and learn about AAV production with ELEVECTA® – Stable Producer Cell Lines enabling full scalability, consistent quality and a robust production process.
Cell & Gene Therapy Insights – May 15, 2020
Cevec Pharmaceuticals GmbH has launched a new, scalable production platform for AAV gene therapy vectors.
At the time of Cevec Pharmaceuticals’s announcement, US researchers reported that AAV gene therapy might be the most promising way to bridge the therapeutic gap until a COVID-19 vaccine is available.
European Biotechnology, April 29, 2020